Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 57.6 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus CD117, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus CD117, His Tag (Cat. No. CD7-C52H9) is more than 90% and the molecular weight of this protein is around 68-88 kDa verified by SEC-MALS.
Immobilized Cynomolgus CD117, His Tag (Cat. No. CD7-C52H9) at 2 μg/mL (100 μL/well) can bind Biotinylated Human SCF, Avitag,His Tag (Cat. No. SCF-H82E1) with a linear range of 0.2-5 ng/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | EU | Leukemia, Myeloid, Acute; Mastocytosis | Novartis Europharm Ltd | 2017-04-28 | Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | Japan | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Otsuka Holdings Co Ltd | 2012-12-14 | Blast Crisis; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Gastrointestinal Stromal Tumors; Philadelphia Chromosome; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Neoplasms; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Head and Neck Neoplasms; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia; Hematologic Neoplasms | Details |
Avapritinib | BLU-285; CS-3007 | Approved | Blueprint Medicines Corp | Ayvakit, Ayvakyt, 泰吉华 | EU | Mastocytosis, Systemic | Blueprint Medicines (Netherlands) Bv | 2020-01-09 | Solid tumours; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Mastocytosis, Systemic; Central Nervous System Neoplasms; Leukemia, Mast-Cell; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Adenocarcinoma | Details |
Lenvatinib Mesylate | ER-203492-00; E-7080; MK-7902 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | Japan | Carcinoma, Renal Cell | Merck Sharp & Dohme Corp | 2015-02-13 | Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumors; Neurofibroma, Plexiform; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neurofibrosarcoma; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Glioblastoma; Neoplasms; Hodgkin Disease; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma | Details |
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Thyroid Neoplasms | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Esophageal Squamous Cell Carcinoma; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Bile Duct Diseases; Thyroid Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Osteoma; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | EU | Thyroid Neoplasms | Bayer AG | 2005-12-01 | Liver Neoplasms; Leukemia, Myeloid; Lymphoma, B-Cell, Marginal Zone; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Fibromatosis, Aggressive; Leiomyosarcoma; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Solid tumours; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Recurrence; Carcinoma, Renal Cell; Esophageal Neoplasms; Vipoma; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Hemangiosarcoma; Carcinoid Tumor; Carcinoma; Insulinoma; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Multiple Endocrine Neoplasia Type 2a; Hypertension, Portal; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Wilms Tumor; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large-Cell, Immunoblastic; S | Details |
Dasatinib Hydrate | BMS-354825; NSC-732517 | Approved | Bristol-Myers Squibb Company | 施达赛, Spricel, Sprycel, Spraysel | Mainland China | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Bristol-Myers Squibb Pharma Eeig | 2006-06-28 | Astrocytoma; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Lung Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Bone; Primary Myelofibrosis; Gliosarcoma; Burkitt Lymphoma; Peritoneal Neoplasms; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Neurofibrosarcoma; Sarcoma; Cholangiocarcinoma; Brain Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Prostatic Neoplasms; Neoplasm Metastasis; Mastocytosis; Tongue Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Large Granular Lymphocytic; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Melanoma; Heart Arrest; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Hemangiopericytoma; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Laryngeal Neoplasms; Waldenstrom Macroglobuli | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | Mainland China | Carcinoma, Renal Cell | Novartis Pharma Schweiz Ag | 2009-10-19 | Peritoneal Neoplasms; Lymphoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Thyroid Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Uterine Cervical Diseases; Choriocarcinoma; Colorectal Neoplasms; Neuroblastoma; Osteosarcoma; Gastrinoma; Psoriasis; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); von Hippel-Lindau Disease; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Paraganglioma; Thyroid Cancer, Papillary; Neoplasm Metastasis; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Prostatic Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Glioma; Germinoma; Carcinoma, Neuroendocrine; Carcinoma, Embryonal; Carcinoma, Squamous Cell; Telangiectasia, Hereditary Hemorrhagic; Thyroid Carcinoma, Anaplastic; Neoplasms; Carcinoid Tumor; Herpes Genitalis; Pheoc | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Pharmaceuticals Ltd (China) | 索坦, Sutent | Japan | Pancreatic neuroendocrine tumors (pNET) | Pfizer Inc | 2006-01-26 | Teratoma; Ovarian Neoplasms; Fibromatosis, Aggressive; Solid tumours; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Leiomyosarcoma; Fibrosarcoma; HIV Infections; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Ependymoma; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangioblastoma; Carcinoma, Islet Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Leukemia, Hairy Cell; Abdominal Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Pelvic Neoplasms; Pheochromocytoma; Glioblastoma; Neurofibromatoses; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Neoplasms; I | Details |
Olverembatinib | D-824; GZD-824; APG-1351; GIBH-824; HQP-1351 | Approved | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | 耐立克 | Mainland China | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase | Guangzhou Shunjian Biomedical Technology Co Ltd | 2021-11-25 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myeloid; Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors | Details |
Ripretinib | DCC-2618 | Approved | Deciphera | 擎乐, Qinlock | United Kingdom | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors | Details |
Imatinib mesylate | CGP-57148B; CGP-57148; STI-571; QTI-571; CTI-571; VR325; AER-901; YD-312; TNX-201 | Approved | Novartis Pharma Ag | glivic, 格列卫, Gleevec, Ruvise, Glivec, Gleevec/Glivec | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Novartis Pharma Ag | 2001-05-10 | Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome; Leukemia, Myeloid, Accelerated Phase; Ovarian germ cell tumor; Ovarian Neoplasms; Fibrosarcoma; Solid tumours; Loiasis; Lymphoma, B-Cell, Marginal Zone; Genital Diseases, Male; Head and Neck Neoplasms; Neoplasm, Residual; Hematopoietic stem cell transplantation (HSCT); Diabetes Mellitus, Type 1; Hypertension, Pulmonary; Leukemia, Hairy Cell; Histiocytoma, Malignant Fibrous; Rectal Neoplasms; Stomach Neoplasms; Abdominal Neoplasms; Desmoplastic Small Round Cell Tumor; Polycythemia Vera; Genital Neoplasms, Male; Rhinitis, Allergic, Seasonal; Myeloproliferative Disorders; Scleroderma, Systemic; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Dermatofibrosarcoma; Seminoma; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Plasmacytoma; Immunoglobulin Light-chain Amyloidosis; Hodgkin Disea | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Sorafenib Tosylate/MG-K10 | MG-D-1609 | Phase 2 Clinical | Solid tumours | Details | |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis) | LOP-628 | Novartis Pharma Ag | Details | ||
CDX-0158 | CDX-0158; KTN-0158 | Yale University, University Of Toronto - St. George Campus | Details | ||
T-1301 | T-1301; DBPR-216 | Taivex Therapeutics Corp | Details | ||
AKN-028 | BVT-II; AKN-028; BVT-63628 | Akinion | Details | ||
MGTA-117 | MGTA-117 | Phase 2 Clinical | Heidelberg, Magenta Therapeutics Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
GS-0174 | GS-0174 | Phase 1 Clinical | Forty Seven Inc | Hematologic Neoplasms | Details |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma | Details |
THE-630 | THE-630 | Phase 2 Clinical | Theseus Pharmaceuticals Inc | Digestive System Diseases; Gastrointestinal Diseases; Neoplasms; Neoplasms, Connective and Soft Tissue; Digestive System Neoplasms; Gastrointestinal Stromal Tumors; Neoplasms, Connective Tissue; Gastrointestinal Neoplasms | Details |
THB-001 | THB-001 | Phase 1 Clinical | Novartis Corp | Gastrointestinal Diseases; Chronic Urticaria; Respiratory Tract Diseases | Details |
Briquilimab | JSP-191; AMG-191 | Phase 2 Clinical | Amgen Inc | Myelodysplastic Syndromes; Severe Combined Immunodeficiency; Leukemia, Myeloid, Acute; Granulomatous Disease, Chronic | Details |
TR-64 | TR-64 | Phase 1 Clinical | Tarapeutics Science Inc | Solid tumours; Gastrointestinal Stromal Tumors | Details |
Barzolvolimab | CDX-0159 | Phase 2 Clinical | Yale University, University Of Toronto - St. George Campus | Chronic Urticaria; Skin Diseases; Prurigo; Urticaria | Details |
Chiauranib | CS-2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular | Details |
Imatinib dry powder inhalation (Aerovate Therapeutics) | AV-101(Aerovate Therapeutics) | Phase 3 Clinical | Pulmonary Arterial Hypertension | Details | |
Bezuclastinib | PLX-9486; CGT-9486 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Gastrointestinal Stromal Tumors; Neoplasm Metastasis; Mastocytosis | Details |
Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
This web search service is supported by Google Inc.